Deals this week: FenoLogica Biosciences, CareDx, NuSirt Biopharma

22 September 2016 (Last Updated September 22nd, 2016 18:30)

FenoLogica Biosciences, a life sciences company based in Seattle, Washington, US, has signed a licensing and collaboration agreement with Pacific Northwest Research Institute (PNRI), a biomedical research institute also based in Seattle.

FenoLogica Biosciences, a life sciences company based in Seattle, Washington, US, has signed a licensing and collaboration agreement with Pacific Northwest Research Institute (PNRI), a biomedical research institute also based in Seattle.

Pursuant to the agreement, FenoLogica will collaborate with PNRI’s scientists to develop and commercialise a biology platform, which will be formed by combining novel quantitative biology measurement techniques with cloud-based analytical tools.

The platform, which is applicable to a variety of high-content microbiology environments, will provide researchers with insights about the causes of disease and helps them in accelerating the discovery of new treatment options. The first platform is expected to be released in early-2018.

"The companies have signed a product license arrangement, pursuant to which they will develop a hypospray-delivered proprietary solution that would cease the progression of Alzheimer's."

Molecular diagnostic solutions provider, CareDx, has announced public offering of 2.25m of its common stock shares, at a price of $4 each. The company has also announced a 30-day option to the underwriters to buy up to an additional 15% of the common stock shares.

The gross proceeds will be used partly to fund the development of CareDX’s proprietary donor-derived cell-free DNA detection test, named Allosure, and partly for other clinical trial and product commercialisation purposes, corporate and working capital purposes, and for acquisitions and investments.

NuSirt Biopharma has announced a new collaboration with One Way Liver (OWL Metabolomics) to advance the treatment options for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Pursuant to the agreement, the two companies will conduct clinical trials to evaluate drug-induced lipidomic changes in the body for NAFLD and NASH. They will then find out the potential of developing a unique liquid-biopsy companion diagnostic (CDx) for NS-0200, NuSirt's research candidate for fatty liver.

Transdermal Delivery Solution, a developer of spray-on drug delivery systems, has announced a partnership with ALZYN, an early-stage company focused on addressing Alzheimer's disease (AD).

The companies have signed a product license arrangement, pursuant to which they will develop a hypospray-delivered proprietary solution that would cease the progression of Alzheimer's.

Pathogen-testing solution provider, Roka Biosciences, has announced private placement of 22,500 of its series A convertible preferred stock shares, which are subscribed to by accredited investors, to raise approximately $22.5m in gross proceeds.

The company will use the proceeds for general corporate purposes.